ArticleOncology letters2017

Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.

Yukiko Komeno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.